What is Core Biogenesis?
Core Biogenesis is at the forefront of biodesign, specializing in the creation of innovative solutions for regenerative medicine and longevity skincare. The company leverages plants as sophisticated biofactories to produce high-value recombinant proteins. These proteins are targeted for use in the Life Science and Beauty & Wellness industries. Core Biogenesis' proprietary platform technology is designed to enhance protein stability by directing them to plant oleosomes, a novel approach to bioproduction. Through this innovation, the company aims to drive advancements in sustainable bioproduction and contribute to a more environmentally conscious future.
How much funding has Core Biogenesis raised?
Core Biogenesis has raised a total of $10.5M across 1 funding round:
Series A
$10.5M
Series A (2022): $10.5M with participation from Thia Ventures, Blue Horizon Ventures, and XAnge
Key Investors in Core Biogenesis
Thia Ventures
Thia Ventures is a fund management company with a focus on investments at the intersection of food, biotechnology, and health, aiming to support innovative ventures in these sectors.
Blue Horizon Ventures
Blue Horizon Ventures is a food technology-focused venture capital fund supporting a sustainable food system through innovation, with a primary focus on plant-based proteins and cellular agriculture.
XAnge
XAnge is a European early-stage venture capital firm with extensive experience in backing transformative startups from Seed to Series B, focusing on scaling tech companies globally.
What's next for Core Biogenesis?
With the recent major strategic investment, Core Biogenesis is poised for significant expansion. The capital is anticipated to fuel further research and development, scale production capabilities, and broaden market reach within the regenerative medicine and longevity sectors. This funding round, characterized as enterprise-level, suggests a strong validation of the company's technology and market potential, positioning Core Biogenesis to solidify its leadership in plant-based bioproduction for high-value proteins. Future strategic partnerships and product development are likely to be key focuses as the company moves into its next phase of growth.
See full Core Biogenesis company page
